biotech · Relapsed or Refractory B-cell Malignancies · Solid Tumor · RXRX
RECURSION PHARMACEUTICALS
RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Staten Island, USA
- Employees
- 11
- Programs
- 9
- Drugs
- 2
- Patents
- 4
RECURSION PHARMACEUTICALS projects
9 ClinicalTrials.gov programs sponsored by RECURSION PHARMACEUTICALS.
RECURSION PHARMACEUTICALS has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
REC-2282
RECURSION PHARMACEUTICALS, INC.
Neurofibromatosis Type 2
1 trial -
GTAEXS617
RECURSION PHARMACEUTICALS, INC.
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
REC-1245
RECURSION PHARMACEUTICALS, INC.
Unresectable
1 trial -
REC-3964
RECURSION PHARMACEUTICALS, INC.
Recurrent Clostridioides Difficile Infection
1 trial -
REC-4881
RECURSION PHARMACEUTICALS, INC.
AXIN1 Gene Mutation
1 trial -
REC-4881
RECURSION PHARMACEUTICALS, INC.
Familial Adenomatous Polyposis
1 trial -
REC-994
RECURSION PHARMACEUTICALS, INC.
Cerebral Cavernous Malformation
1 trial -
EXS73565
RECURSION PHARMACEUTICALS, INC.
Relapsed or Refractory B-cell Malignancies
1 trial -
EXS74539
RECURSION PHARMACEUTICALS, INC.
Solid Tumor
1 trial
Frequently asked questions
How many clinical projects does RECURSION PHARMACEUTICALS have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.